Novartis’ heart failure drug Entresto gets top US, EU recommendation

pharmafile | May 23, 2016 | News story | Research and Development, Sales and Marketing Ernesto, Novartis, heart failure, regulation 

Swiss drugmaker Novartis (VTX: NOVN) said its heart failure drug Entresto (sacubitril/ valsartan) has secured top recommendations in the US and EU. 

The company said Entresto has won Class I recommendation from the American College of Cardiology (ACC), the American Heart Association (AHA) and the Heart Failure Society of America (HFSA) in the US, and the European Society of Cardiology in the EU. 

Entresto is now a standard therapy for heart failure with reduced ejection fraction (HFrEF) as an alternative to an ACE inhibitor, in the US, Novartis said. 

Heart failure is a debilitating and life-threatening condition, which impacts over 60 million people worldwide. It is the leading cause of hospitalization in people over the age of 65. About half of people with heart failure have HFrEF. Reduced ejection fraction means the heart does not contract with enough force, so less blood is pumped out. Heart failure presents a major and growing health-economic burden that currently costs the world economy $108 billion every year. 

Anjali Shukla

Related Content

AstraZeneca’s Forxiga approved in China for chronic heart failure treatment

AstraZeneca has announced that Forxiga (dapagliflozin) has been approved in China to reduce the risk …

Ionis and Novartis partner for CVD treatment programme

Ionis Pharmaceuticals has announced that it has entered into a new collaboration and license agreement …


Novartis acquires Chinook Therapeutics for $3.5bn

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …

Latest content